Back to products
Cervical Cancer PAX1 / JAM3 dual-gene methylation

CISCER®Cervical Cancer Methylation Test (PAX1/JAM3)

Dual-gene methylation test, empowering cervical cancer prevention

PAX1/JAM3 dual-gene combined test using non-invasive cervical exfoliated cell sampling, accurately identifying CIN2+ high-grade lesions for precise triage.

NMPA Registration No.
20233400253
Date Approved
2023

Recommended companion kits

Use the DNA Isolation and Purifying Kit (Beijing Medical Device No. 20210020) for DNA extraction and purification, followed by DNA Methylation-Lightning MagPrep (Beijing Medical Device No. 20200110) for bisulfite conversion.

Clinical Data

Robust clinical data support

Based on multi-center registered clinical trials, sensitivity and specificity both reach industry-leading levels.

Sensitivity (CIN2+)89.60%
Registered clinical trial
Specificity96.50%
Registered clinical trial
Sensitivity (CIN3+)95.96%
Registered clinical trial
1,968cases
Registered clinical samples
Cervical exfoliated cells (non-invasive sampling)
Sample Type
Target Population

Who needs this test?

  • Precision triage for HPV-positive individuals
  • Women with mild cytological abnormalities (ASC-US)
  • Cervical cancer screening for postmenopausal women
  • Treatment response and recurrence monitoring for cervical lesions
Clinical Scenarios

How is it applied clinically?

  • Opportunistic and population-based cervical cancer screening
  • Colposcopy referral decisions after HPV-positive results
  • Post-treatment follow-up for high-grade cervical lesions
  • Women's health dual-screening programs at health checkup centers
Highlights

Why choose us

01

Dual-gene (PAX1/JAM3) combined test with superior performance

02

Supported by multi-center study data with 10,000+ paired cases

03

Recommended by multiple domestic and international expert consensus and guidelines

04

Ongoing nationwide multi-center real-world studies

FAQ

Frequently asked questions about this test

What is the CISCER test?

CISCER is a Class III in vitro diagnostic device (NMPA Reg. No. 20233400253) that detects PAX1/JAM3 dual-gene methylation in cervical exfoliated cells for early cervical cancer screening and triage of HPV-positive individuals.

How accurate is the CISCER test?

Registration clinical trial data (1,968 samples) show 89.60% sensitivity for CIN2+, 96.50% specificity, and 95.96% sensitivity for CIN3+, supported by a 10,000-sample multi-center real-world study.

Is the CISCER sampling procedure painful?

No. The test requires only cervical exfoliated cells collected non-invasively during a routine gynecological exam — no biopsy needed.

I tested HPV-positive. Should I also get the CISCER test?

Recommended. Most HPV infections are transient. CISCER methylation testing assesses cancer risk at the lesion level, helping identify who genuinely needs colposcopy referral and avoiding over-diagnosis and over-treatment.

Who is suitable for the CISCER test?

HPV-positive individuals, women with mild cytological abnormalities (ASC-US), postmenopausal women, and patients monitoring efficacy or recurrence before and after treatment for cervical lesions.

Next step

Request the IFU, clinical summary and pricing

Tell us your institution type and intended use. We reply within 1–2 business days with the documents below, and can arrange a technical call with our clinical team.

  • IFU, registration certificate and sample requirements
  • Clinical performance summary and published papers
  • Distributor terms, kit configuration and logistics
Evidence

Cervical Cancer Related Publications

Standardized Application

Related Guidelines & Consensus